Short Term Recommendations from NCCN Guidelines® & ASCO® Regarding use of Hematopoietic Growth Factors during COVID-19 Pandemic*
Due to COVID-19 pandemic, the short-term recommendations from the NCCN Guidelines® and ASCO® have lowered the threshold for the use of myeloid growth factors from those chemotherapy regimens which have a 20% or higher risk of febrile neutropenia to now include those regimens with a risk of 10-20%, which includes all of the intermediate risk chemotherapy regimens.
Coherus COMPLETE is a trademark and UDENYCA is a registered trademark of Coherus BioSciences, Inc. ©2020 Coherus BioSciences, Inc. All rights reserved.
0920-COH-P539